XUANZHUBIO-B(02575): Innovative drug Anjiuwei successfully renewed to be included in the National Basic Medical Insurance Drug Catalog for 2025.

XUANZHUBIO-B(02575) has announced that after a simple medical insurance renewal with the National Healthcare Security Administration (National Health Insurance Administration), the innovative drug Anailerazone enteric-coated tablets (trade name: Anjiuwei), independently developed by the company, will continue to be included in the new version of the National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug List (2025) that will take effect from January 1, 2026. As the first and only domestically developed proton pump inhibitor, Anjiuwei was approved for market in China in June 2023 for the treatment of duodenal ulcers, and was first included in the National Basic Medical Insurance Drug List in December 2023. The successful renewal of Anjiuwei in the 2025 National Basic Medical Insurance Drug List will benefit market stability and continue to benefit more patient populations, improve the product's penetration in related indications, and inject momentum into the long-term growth of Anjiuwei.